ESPERITE (ESP) : L1 Capital subscribes to the 18th tranche of investment today
ESPERITE (ESP) : L1 Capital subscribes to the 18th tranche of investment today
Amsterdam, The Netherlands – 17 May 2018
read more
ESPERITE (ESP) : L1 Capital subscribes to the 18th tranche of investment today
Amsterdam, The Netherlands – 17 May 2018
read more
Amsterdam, the Netherlands – 16 May 2018
Esperite’s biotech company The Cell Factory, Belgium has received funding from the European Union’s Horizon 2020 research and innovation Programme for development and characterization of the extracellular vesicles (EVs) drug CF-MEV-126 for treatment of stroke. The project is focused on the development of the 2nd generation EVs drug, with enhanced anti-inflammatory and neuroprotective activities.
Amsterdam, The Netherlands – 3 May 2018
ESPERITE (ESP) delays publication of Annual Report 2017
Amsterdam, The Netherlands – 30 April 2018
Continuation of support to Esperite’s strategy, commercial activities and development of innovative technologies in the field of genetics and regenerative medicines.
Amsterdam, The Netherlands – 11 April 2018
Esperite with its biotech company The Cell Factory has acquired from OPBG the full rights to the IP and the international patent family covering the invention and the therapeutic use of the EV’s products. In collaboration with Women’s and Children’s Health Department of the University of Padua, Italy they are presenting the new generation EV’s biologic drugs bio-activated with Annexin V targeting multiple inflammatory diseases i.e.: Crohn’s disease, drug resistance epilepsy, stroke. The experimental results will be presented during GISM congress in Assisi, Italy in April and ISEV meeting in Barcelona, Spain in May 2018.
Amsterdam, the Netherlands – 29 March 2018
ESPERITE (ESP) : L1 Capital subscribes to the 16th tranche of investment today
Amsterdam, The Netherlands – 2 March 2018
Continuation of support to Esperite’s strategy, commercial activities and development of innovative technologies in the field of genetics and regenerative medicines.
Amsterdam, The Netherlands – 16 February 2018
Esperite with BGI sequencing technology will enable the global population easier access to the gold standard in clinical genetic testing.
Amsterdam, The Netherlands – 31 January 2018
ESPERITE (ESP) : L1 Capital subscribes to the 14th tranche of investment today
Amsterdam, The Netherlands – 31 January 2018